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Abstract
Depression frequently accompanies Parkinson’s disease and often precedes the onset of
motor symptoms. This study aimed to evaluate the impact of depression on motor compen-
sation in patients with de novo Parkinson’s disease. This retrospective cohort study ana-
lyzed data from 474 non-demented patients with de novo Parkinson’s disease (mean age,
64.6±9.8 years; 242 men) who underwent both dopamine transporter PET scan and depres-
sion assessment using the Beck Depression Inventory at baseline. Patients were classified
into tertiles by Beck Depression Inventory score. At baseline, high-tertile group (Beck
Depression Inventory score15, n = 157) showed more severe motor deficits and lower
cognitive function than low-tertile group (Beck Depression Inventory score7, n = 158,
P = 0.034 and P = 0.008, respectively). Greater motor deficits in high-tertile group than low-
tertile group remained significant after controlling for dopamine transporter binding in the
posterior putamen, as well as other confounding variables. During follow-up of a median
duration of 47 months, high-tertile group received higher levodopa-equivalent doses for
symptom control than did low-tertile group after controlling for age, gender, and initial motor
deficit severity. These results demonstrate that depression in de novo Parkinson’s disease
is associated with motor deficit severity at baseline and dose of PD medications during fol-
low-up, suggesting that the presence of depression in de novo Parkinson’s disease repre-
sents poor motor compensation.
Introduction
Increasing evidence supports the heterogeneity of Parkinson’s disease (PD) in its clinical pre-
sentation and prognosis [1, 2]. Identification of PD subtypes may help understand underlying
disease mechanisms, to predict disease course, and to design more efficient personalized
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therapeutic strategies [3]. Among the potential factors delineating PD subtypes, early burden
of non-motor symptoms accompanied in PD has been recognized as an important prognostic
marker indicative of poor motor outcomes [4, 5].
Motor symptoms in PD do not develop until approximately half of mesencephalic dopami-
nergic neurons are lost [6], suggesting the presence of significant motor system compensation.
This compensatory ability may reflect an individual’s capacity to tolerate neuropathological
lesions, i.e., dopamine depletion in PD, known as neural reserve [7]. Patients with de novo PD,
who had either olfactory dysfunction or REM sleep behavior disorder, exhibited greater motor
deficits than those without these symptoms at similar level of dopamine depletion [8, 9], sug-
gesting that early accompaniment of these non-motor symptoms is associated with reduced
compensatory ability in PD.
Depression is another representative non-motor symptom that may precede the onset
of motor symptoms [10]: early accompaniment of depression in PD has been proposed to
result from the pathological involvement of the monoaminergic nuclei in the brainstem [11].
Accordingly, early accompaniment of depression in de novo PD indicates widespread involve-
ment of pathological lesions, which in turn may limit compensatory ability in PD. Despite a
previous report showing more physical impairments in depressed patients with early PD com-
pared to non-depressed patients [12], dopamine depletion patterns associated with depression
in early PD still remains controversial [13, 14]. To test whether early accompaniment of
depression is associated with reduced ability of motor compensation, we analyzed dopamine
transporter PET scans and depression levels in patients with de novo PD.
Material and methods
Study populations
This retrospective cohort study selected subjects from the Yonsei Parkinson Center database
(consecutive patients sampled from April 2009 to September 2015) who fulfilled the follow-
ing selection criteria: (1) had drug-naïve PD; (2) underwent DAT imaging using [18F] N-
(3-fluoropropyl)-2b-carbon ethoxy-3b-(4-iodophenyl) nortropane (FP-CIT) PET scans; and
(3) underwent the Beck Depression Inventory (BDI) assessment. PD in these patients was
diagnosed according to the clinical criteria of the UK Brain Bank, the presence of appropriate
DAT uptake defects on FP-CIT PET scans, and the presence of PD drug response during a
follow-up period >3 months. Part III of the Unified Parkinson’s Disease Rating Scale
(UPDRS-motor) was used to assess PD motor symptom severity, while the Mini-Mental
State Examination (MMSE) was used to measure cognitive function in each patient at the
time of the FP-CIT PET acquisition. Patients who took antidepressants or had an MMSE
score < 24 were excluded. We received approval from the Yonsei University Severance Hos-
pital ethical standards committee on human experimentation for this study. Because this
study was a retrospective analysis of pre-existing medical data, the need to obtain patient
consent was waived.
Assessment of depression
The BDI was developed to provide a quantitative assessment of depression intensity based on
clinical observations, and has been widely used in patients with PD for screening and measur-
ing depression [15]. The Korean version of the BDI has been developed, validated, and used to
assess depression in the general population, as well as in patients with PD [16, 17]. Although
BDI reliability and validity were demonstrated for assessment of depression in PD, the recom-
mended cut-off point for discriminating between depressed and non-depressed patients with
PD varies among studies, ranging from 7–18 points [18]. Leentijens et al. suggested that a
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single BDI cut-off score to distinguish depressed from non-depressed PD patients is not feasi-
ble, because the sum of the sensitivity and specificity was found to change little over a broad
range of possible cut-off scores ranging from 6/7 to 16/17 points [19]. Thus, in this study,
we classified patients into three tertile groups by BDI score instead of using a single cut-off
value. Because BDI score is known to represent depression levels in patients with PD [20], we
assumed that high-tertile group encompassed only depressed patients and low-tertile group
encompassed only non-depressed patients, while middle-tertile group encompassed a mix of
depressed and non-depressed patients.
Image acquisition and quantitative analyses
To measure striatal DAT binding, we conducted DAT scans using FP-CIT with a GE Discov-
ery STe PET-CT scanner (GE Healthcare Technologies, Milwaukee, WI, USA). In all patients,
FP-CIT PET scans were performed in drug-naïve state before PD diagnosis. The details of the
PET-CT image acquisition were the same as previously described [8].
Quantitative analyses of FP-CIT PET data were performed following a previously described
procedure [8, 21], based on volumes of interest (VOIs): 12 VOIs of bilateral striatal subregions
and one occipital VOI were drawn in the same way as described in previous studies. Using
DAT concentration in each VOI, DAT binding for each VOI was estimated using the specific/
nonspecific binding ratio as a surrogate. This was defined as follows: (mean standardized
uptake value of the striatal sub-region VOIs—mean standardized uptake value of the occipital
VOI) / mean standardized uptake value of the occipital VOI.
Longitudinal assessment of the change in levodopa-equivalent dose
After diagnosis of PD, two movement disorder specialists (P.H.L. and Y.H.S.) adjusted the
doses of PD medications for effective symptom control at 3- to 6-month intervals. At each
visit, the doses of PD medications were checked, and levodopa-equivalent dose (LED) was cal-
culated based on a previously described methodology [22].
Statistical analyses
Data are expressed as means ± standard deviations. An analysis of variance test with post hoc
Bonferroni correction was used to compare numeric variables, while a χ2 analysis was used
to compare non-parametric variables among the three tertile groups. A general linear model
was used to compare differences in UPDRS-motor scores among the three groups after con-
trolling for DAT binding in the posterior putamen and other potential confounding vari-
ables. A linear mixed model was used to compare rates of longitudinal LED changes among
the three tertile groups. Five fixed effects were included in the model: four were between-
subject effects (tertile group, age at PD onset, gender, and baseline UPDRS-motor score),
and one was a within-subject effect (time). Since most increases in LED occur within the
first six months, we regarded time as a categorical variable with a 6-month interval, up to 48
months (when more than 49% of the patients were followed-up). Patients with follow-up
durations of 18 months or longer were enrolled in this analysis. The effect of the tertile
groups on changes in LED over time was tested with a time × tertile group interaction term,
after controlling for age at PD onset, gender, and initial UPDRS-motor score. SPSS Statistics
23 (IBM SPSS, Armonk, NY, USA) was used to perform the statistical analyses. P-values less
than 0.05 were considered significant.
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Results
Baseline demographic and clinical characteristics
A total of 474 patients (mean age, 64.6 ±9.8 years; range, 37–89 years; 242 men) were included
in our analysis. The mean symptom duration was 18.3 ± 17.3 months, mean UPDRS-motor
score was 21.7 ± 9.4, and mean BDI score was 12.1± 8.3. One hundred fifty-eight patients were
in low-tertile group (BDI score7), 159 in middle-tertile group (BDI score, 8–14) and 157
inhigh-tertile group (BDI score15). Patients’ baseline clinical and demographic characteris-
tics are shown in Table 1. UPDRS-motor score and MMSE score differed among the three
groups (P = 0.025 and P = 0.008, respectively); a post hoc analysis indicated that high-tertile
group had higher UPDRS-motor scores and lower MMSE scores than did low-tertile group
(P = 0.034 and P = 0.008, respectively). Gender distributions tended to differ among the three
groups (P = 0.052); more women (55.4%) were in high-tertile group, while more men (58.8%)
were in low-tertile group. Other variables, including age and symptom duration, were compa-
rable among the three groups.
DAT binding and initial motor deficits
DAT bindings in all striatal subregions were similar among the three groups (Table 2). A gen-
eral linear model showed that high-tertile group had higher UPDRS-motor scores than low-
tertile group (P = 0.045) after controlling for age, gender, symptom duration, MMSE score,
and DAT binding in the posterior putamen (Table 3). However, the interaction effect between
patient group and DAT binding in the posterior putamen on UPDRS-motor scores did not
differ among the groups (Fig 1).
Longitudinal changes in levodopa-equivalent dose
The median follow-up duration was 47 months (range, 4 to 107 months). There was no signifi-
cant interaction between the tertile groups and time in the mixed model (P = 0.193), indicating
that the pattern of longitudinal changes in LED did not differ among the tertile groups. How-
ever, high-tertile group required higher LEDs for symptom control compared to low-tertile
group over the follow-up period. Middle-tertile group received lower LEDs than high-tertile
group after follow-up of three years or longer (Table 4, Fig 2).
Table 1. Baseline clinical and demographic characteristics.
Variables Depression level, tertile P value
High
(n = 157)
Middle
(n = 159)
Low
(n = 158)
Beck Depression Inventory range  15 8–14  7
mean 21.4 ± 6.9 10.7 ± 1.9 4.1 ± 2.2
Age (years) 64.0 ± 9.4 64.6 ± 10.0 65.1 ± 10.0 0.589
Gender (% women) 55.4 49.7 41.8 0.052
Symptom duration (months) 18.4 ± 14.9 19.3 ± 19.7 17.1 ± 17.0 0.528
Mini-Mental Status Examination 27.0 ± 1.9 27.4 ± 1.8 27.6 ± 1.7 0.008
UPDRS-motor score 22.8 ± 9.5 22.3 ± 9.1 20.1 ± 9.5 0.025
UPDRS-motor, Part III of the Unified Parkinson’s Disease Rating Scale.
Data are means ± SDs unless otherwise indicated.
, significantly different from high-tertile group by post hoc analysis.
https://doi.org/10.1371/journal.pone.0203303.t001
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Discussion
This study demonstrated that depressionin de novo PD is associated with initial motor deficit
severity: high-tertile group exhibited more severe motor deficits than did low-tertile group,
even after controlling for DAT binding in the posterior putamen, as well as other potential
confounding variables. In addition, high-tertile group received higher LEDs to control PD
symptoms, compared with low-tertile group, during the follow-up period after controlling
initial motor deficit severity and other potential confounding variables. These results suggest
that the presence of depression in de novo PD indicates poor motor compensation at baseline,
which in turn is maintained during follow-up period. On the contrary to our initial expecta-
tion, the amounts of striatal DAT depletion weresimilar among the three groups.
Table 2. Dopamine transporter binding in striatal subregions.
Variables Depression level, tertile P value
High
(n = 157)
Middle
(n = 159)
Low
(n = 158)
Ventral striatum Mean 2.23 ± 0.61 2.13 ± 0.60 2.20 ± 0.53 0.242
Left 2.30 ± 0.63 2.17 ± 0.67 2.24 ± 0.52 0.185
Right 2.17 ± 0.62 2.08 ± 0.58 2.16 ± 0.56 0.344
Anterior caudate Mean 2.20 ± 0.70 2.15 ± 0.75 2.19 ± 0.64 0.806
Left 2.21 ± 0.71 2.15 ± 0.75 2.17 ± 0.63 0.646
Right 2.18 ± 0.73 2.16 ± 0.77 2.20 ± 0.69 0.894
Posterior caudate Mean 1.44 ± 0.55 1.44 ± 0.60 1.45 ± 0.58 0.979
Left 1.40 ± 0.54 1.39 ± 0.60 1.43 ± 0.58 0.768
Right 1.48 ± 0.60 1.50 ± 0.64 1.47 ± 0.62 0.932
Anterior putamen Mean 2.26 ± 0.63 2.28 ± 0.70 2.36 ± 0.63 0.329
Left 2.27 ± 0.66 2.27 ± 0.73 2.35 ± 0.61 0.449
Right 2.24 ± 0.68 2.29 ± 0.74 2.37 ± 0.72 0.284
Ventral putamen Mean 1.47 ± 0.43 1.49 ± 0.43 1.54 ± 0.43 0.291
Left 1.43 ± 0.43 1.43 ± 0.46 1.48 ± 0.41 0.560
Right 1.50 ± 0.51 1.55 ± 0.50 1.61 ± 0.55 0.217
Posterior putamen Mean 1.36 ± 0.46 1.40 ± 0.49 1.45 ± 0.48 0.210
Left 1.36 ± 0.49 1.38 ± 0.56 1.43 ± 0.50 0.445
Right 1.35 ± 0.56 1.42 ± 0.57 1.47 ± 0.60 0.198
Data are means ± SDs.
https://doi.org/10.1371/journal.pone.0203303.t002
Table 3. Influence of depression level and dopamine transporter binding in the posterior putamen on UPDRS-motor score.
Unadjusted Adjusted
B (S.E.) P value B (S.E) P value
Mean DAT binding -4.93 (0.88) <0.001 -4.67 (0.87) <0.001
The level of depression
High-tertile Reference Reference
Middle-tertile -0.24 (1.02) 0.814 -0.26 (1.01) 0.798
Low-tertile -2.16 (1.03) 0.032 -2.05 (1.02) 0.045
UPDRS-motor, Part III of the Unified Parkinson’s Disease Rating Scale; DAT, dopamine transporter; B, estimated slope; S.E., standard error.
, adjusted for age, gender, symptom duration, and Mini-Mental Status Examination score.
https://doi.org/10.1371/journal.pone.0203303.t003
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Our classification of patients based on BDI-score tertiles might be ambiguous. However,
the cut-off score (7) for the low-tertile group was approximate to the lowest cut-off score
proposed in previous studies of PD and depression [19, 20]. In a previous study, this cut-off
showed a negative predictive value of 1.00 [19], which suggested that the low-tertile group in
this study reasonably represented non-depressed patients with PD. The cut-off score for the
high-tertile group was the same as the cut-off score proposed previously in other studies [23].
This previous cut-off previously estimated a specificity of 0.93 [19]. Additionally, because the
pooled prevalence of clinically relevant depression in PD outpatient settings was approxi-
mately 40% [24], the high-tertile group may well represent depressed patients with PD.
Previous studies repeatedly showed an inverse correlation between depression score and
striatal DAT binding [13, 25, 26]. However, Ceravolo et al. demonstrated that this inverse rela-
tionship was no longer observed in patients with de novo PD [14]. The present results, as well
as those in the latter study, suggest that depression in de novo PD does not require striatal
dopamine depletion. Pathological involvement in the raphe nucleus and locus coeruleus,
Fig 1. A scatterplot showing baseline UPDRS-motor scores and mean DAT binding in the posterior putamen.
High-tertile group (red circles and line) showed higher UPDRS-motor scores at similar DAT binding levels in the
posterior putamen than low-tertile group (blue circles and line). Middle-tertile group (green circles and line) showed
similar UPDRS-motor scores to high-tertile group. UPDRS-motor, Part III of the Unified Parkinson’s Disease Rating
Scale; DAT, dopamine transporter.
https://doi.org/10.1371/journal.pone.0203303.g001
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Table 4. Levodopa-equivalent doses during follow-up.
Time Depression level, tertile Overall P valuea Post-hoc P valueb
High Middle Low High vs. Low High vs. Middle Middle vs. Low
0 0 0 0 NS NS NS
Month 6 373.32 (14.72) 363.62 (13.79) 332.03 (14.11) 0.129 NS 0.328
Month 12 421.16 (14.72) 396.78 (13.79) 350.50 (14.05) 0.002 0.680 0.056
Month 18 449.67 (14.72) 414.56 (13.84) 367.71 (14.05) Group: < 0.001 < 0.001 0.247 0.053
Month 24 474.25 (14.72) 434.76 (13.79) 393.82 (!4.10) Time: < 0.001 < 0.001 0.151 0.114
Month 30 499.61 (14.90) 452.92 (13.79) 416.93 (14.21) Group × Time: 0.193 < 0.001 0.065 0.208
Month 36 530.38 (15.22) 473.26 (14.53) 449.51 (14.72) < 0.001 0.020 0.752
Month 42 558.72 (16.41) 485.72 (15.76) 474.90 (16.81) 0.001 0.004 NS
Month 48 584.12 (17.79) 521.41 (17.36) 524.51 (18.92) 0.007 0.004 NS
NS, not significant.
Data are means (standard error).
aP-values calculated by linear mixed model analysis.
bBonferroni correction P-values of the post-hoc comparison.
https://doi.org/10.1371/journal.pone.0203303.t004
Fig 2. Longitudinal increases in levodopa-equivalent doses. High-tertile group received higher levodopa-equivalent
doses for symptom control than low-tertile group. Middle-tertile group received lower LEDs than high-tertile group
after follow-up of three years or longer. There was no significant interaction between the tertile groups and time in the
mixed model.
https://doi.org/10.1371/journal.pone.0203303.g002
Depression and dopamine depletion in PD
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which occurs prior to PD motor symptoms, according to pathological PD staging by Braak
et al. [27], might be responsible for premotor occurrence of depression in PD [10]. A previous
study using transcranial sonography demonstrated that reduced echogenicity in the raphe
nucleus (suggestive of structural change) was associated with a history of depression prior to
PD onset [28], which supports the aforementioned assumption. In the present study, greater
motor deficits were observed in depressed patients, compared with non-depressed patients,
despite similar levels of striatal dopamine depletion, which again supports the hypothesis that
non-dopaminergic lesion contributes to greater motor deficits in depressed patients.
Previous longitudinal studies have shown that the presence of depression represents a
more rapid decline in cognitive and motor function in patients with PD [29, 30], although a
longer PD duration in depressed than in non-depressed patients in these studies obscure
whether different PD stages might influence their results rather than the presence of depres-
sion. Ravina et al. analyzed a pooled sample of 413 patients with early untreated PD, and
found that baseline depression level was a significant predictor for worsening UPDRS scores
of activities of daily living [12]. This study failed to show more rapid motor progression in
depressed patients compared to non-depressed patients, due to similar pattern of longitudi-
nal changes in LED. However, the maintenance of higher LEDs in depressed patients com-
pared to non-depressed patients during 48-month follow-up, even after controlling initial
motor deficit severity, is somewhat in line with findings of previous studies [12, 29, 30],
which indicates that poor motor compensation at baseline in depressed patients is main-
tained during follow-up.
DAT scans and all baseline assessments were performed in drug-naïve patients that suffi-
ciently excluded the influence of PD medications on these assessments. Nevertheless, this
study has some notable limitations. First, some of the depressed patients in this study might
convert to non-depressed status at follow-up, which has been previously observed [31]. Thus,
initially depressed patients who are persistently depressed at follow-up might differ from those
whose depression goes into remission. Second, a recent report by Fereshtehnejad et al. showed
that non-motor features such as dysautonomia, cognitive impairment, and REM sleep behav-
ior disorder could be important indicators for malignant rapid progressive subtype of PD [2].
Therefore, the association between depression and motor deficit severity shown in the present
study might be confounded by these non-motor features. Third, this study was a retrospective
cross-sectional study, a design that is inadequate for evaluating disease progression. A future
study with prospectively designed longitudinal follow-up is needed to confirm whether
depressed patients with de novo PD represent poor motor outcome.
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